REPROCELL Inc. has recently announced a licensing agreement with Gameto Inc., a female-led biotech firm dedicated to transforming women’s healthcare.
This agreement grants Gameto a non-exclusive right to utilize REPROCELL’s StemRNA™ Clinical Seed iPSCs. Gameto intends to leverage this clinical-grade iPSC line for the development and commercialization of its innovative program, Fertilo, which aims to enhance the IVF (In Vitro Fertilization) and egg freezing processes.
- Fertilo’s Potential: Fertilo is an iPSC-derived solution that matures oocytes outside the body. This groundbreaking approach has the potential to significantly reduce the hormonal burden on patients undergoing fertility treatments. As a result, IVF and egg freezing procedures could become safer, more convenient, and widely accessible.
- Partnership Insights: Chikafumi Yokoyama, the CEO of REPROCELL Inc., expressed his excitement about the collaboration, emphasizing REPROCELL’s commitment to its high-quality StemRNA™ Clinical Seed iPSC platform. On the other hand, Dina Radenkovic, CEO and co-founder of Gameto, highlighted the importance of this license agreement in harnessing the advancements of cell engineering for a more personalized approach to IVF and egg freezing globally. She stressed the need for modern women to have access to enhanced fertility care and acknowledged the partnership with REPROCELL as a significant step towards achieving this goal.
- REPROCELL’s Contribution: REPROCELL specializes in producing iPSCs that align with the regulatory standards set by major global agencies, including the U.S. Food and Drug Administration, European Medicine Agency, and Japan’s Pharmaceuticals and Medical Devices Agency. Their StemRNA™ Clinical iPSC Seed Clones have been evaluated and adopted by numerous biopharmaceutical clients.
- About Gameto: Gameto is a pioneering biotech company that focuses on developing innovative treatment solutions for women’s health, starting with infertility. Led by Dina Radenkovic as CEO and Martin Varsavsky as Chairman, Gameto’s primary program, Fertilo, aspires to revolutionize IVF and egg freezing by maturing eggs outside the body, thereby reducing the need for hormonal injections.
For those interested in learning more about REPROCELL’s StemRNA™ Clinical iPSC, they can visit REPROCELL’s official website.
Source: PR Newswire.